Statement - Over $48 Million Invested for the discovery and development of new medicines by the International Structural Genomics Consortium

Members of Rx&D join the International Structural Genomics Consortium

OTTAWA, Sept. 30, 2011 /CNW/ - Rx&D President Russell Williams made the following statement to complement an announcement made September 28 by members of the International Structural Genomics Consortium (SGC) in London (UK).

"We applaud the international Structural Genomics Consortium (SGC) for investing $48.9 million to further develop its open access research program to support the discovery and development of new medicines.

"We congratulate today Eli Lilly Canada Inc. and Pfizer Canada Inc. for joining the consortium. The other consortium funders comprise the Canadian Institutes for Health Research, GlaxoSmithKline Inc., the Novartis Research Foundation, the Ontario Ministry of Research and Innovation, and the Wellcome Trust.

"Together, these organizations have committed over $48 million to the consortium to sustain another four years of operation. Furthermore, the four pharmaceutical company partners will provide more than $9 million worth of in-kind contributions, primarily medicinal chemistry resources, for collaborative discovery of chemical tool compounds that target disease-linked proteins. The SGC will continue to operate from its founder laboratories at the University of Oxford in the United Kingdom and the University of Toronto in Ontario, Canada as well as benefit from an extensive network of expert scientific collaborators worldwide.

"Enhancing life sciences innovation in Canada depends upon a number of important policy choices, including improving patient access to innovative medicines and vaccines, and ensuring that Canada has a competitive intellectual property regime to better compete with the European Union, the United States and other leading nations.

"It is by working together that we can consolidate the position of Canada as a leader in the provision of health care solutions to people across the country and throughout the world."

Notes For Editors

The Structural Genomics Consortium was formed in 2004 and is a registered UK charity (number 1097737) engaged in open access research of relevance to the science of drug discovery. The Consortium is supported by public and private sector funding. All of its findings are made available to the global research community without restriction.

About Rx&D

Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents 15,000 men and women working for 50 member companies and invests more than $1 billion in research and development each year to fuel Canada's knowledge-based economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.

SOURCE CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX

For further information:

Christine Choury
Media Relations
Telephone: 613.236.0455
Email: cchoury@canadapharma.org

Profil de l'entreprise

CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX&D)

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.